Venture firm Rock Health is considering dipping its toes into biotech after 15 years focused exclusively on digital health, Rock Health Capital general partner Bill Evans tells Axios Pro exclusively.
Why it matters: As AI-developed drugs inch closer to reality, the Bay Area firm is mulling whether to back biotech startups.
